Dergiler / Turkish Journal of Chemistry / 2018 / Cilt: 42 - Sayı: 6

Effect of pH on the complexation of irbesartan with β -, hydroxypropyl-β -, and γ -cyclodextrin: solubility enhancement and physicochemical characterization

Sayfa
1544–1558
Yayın Tarihi
2022-11-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Analysis of 1 H and 13 C-NMR spectra indicated the inclusion of the tetrazole-biphenyl moietywithin the β -CD cavity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The affinity of irbesartan (IRB) to form inclusion complexes with β -cyclodextrin (β -CD), hydroxypropylβ -cyclodextrin (HP-β -CD), and γ -cyclodextrin (γ -CD) was investigated in aqueous buffered solutions at pH 1.7, 4.1,and 7.0.
📊
Temel Bulgular & Veri:Analysis of the UV absorption-pH profiles revealed that IRB has two pKa values: pKa1 = 3.60 (imidazolinonering moiety) and pKa2 = 4.70 (tetrazole moiety).
💡
Sonuç & Katkı:Analysis of 1 H and 13 C-NMR spectra indicated the inclusion of the tetrazole-biphenyl moietywithin the β -CD cavity.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

The affinity of irbesartan (IRB) to form inclusion complexes with β -cyclodextrin (β -CD), hydroxypropylβ -cyclodextrin (HP-β -CD), and γ -cyclodextrin (γ -CD) was investigated in aqueous buffered solutions at pH 1.7, 4.1,and 7.0. Analysis of the UV absorption-pH profiles revealed that IRB has two pKa values: pKa1 = 3.60 (imidazolinonering moiety) and pKa2 = 4.70 (tetrazole moiety). In the presence of 5.0 mmol L −1β -CD, the tetrazole moiety becamemore acidic, indicating its inclusion within the β -CD cavity. Phase-solubility diagrams (PSDs) were obtained for IRBin aqueous buffered solutions of β -CD, HP-β -CD, and γ -CD at pH 4.1 (zwitterionic IRB), pH 1.7 (protonated IRB),and pH 7.0 (deprotonated IRB). Rigorous nonlinear regression analysis of IRB/CD PSDs at pH 4.1, where IRB is poorlysoluble, yielded estimates of complex formation constants (K11) that followed the decreasing order of HP-β -CD >γ -CD>β -CD. The highest solubility enhancement of IRB was achieved by complexation with HP-β -CD at pH 4.1. Theformation of the IRB/β -CD inclusion complex in solution and in the solid state has been proven through NMR, DSC,FT-IR, and XRD studies. Analysis of 1 H and 13 C-NMR spectra indicated the inclusion of the tetrazole-biphenyl moietywithin the β -CD cavity.

🔖

Bu Makaleye Atıf Yap

YOUSEF, F. (2022). Effect of pH on the complexation of irbesartan with β -, hydroxypropyl-β -, and γ -cyclodextrin: solubility enhancement and physicochemical characterization. Turkish Journal of Chemistry, Cilt: 42 - Sayı: 6, 1544–1558. https://ajindex.com/articles/601743

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (24)

  1. Wu, J.; Ding, W.; Zhao, J.; Zang, W.; Matsuura, H.; Horie, M. J. Renin Angiotensin Aldosterone Syst. 2013, 15, 341-347
  2. Vanderheyden, P.; Verheijen, I.; Fierens, F.; De Backer, J.; Vauquelin, G. J. Renin Angiotensin Aldosterone Syst. 2000, 1, 159-165
  3. Weber, M. A. J. Renin Angiotensin Aldosterone Syst. 2003, 4, 62-73
  4. Brunetti, N. D.; De Gennaro, L.; Pellegrino, P. L.; Cuculo, A.; Ziccardi, L.; Gaglione, A.; Di Biase, M. Eur. J. Cardiovasc. Prev. Rehabil. 2011, 18, 424-437
  5. Ranjita, S. J. Pharm. Investig. 2013, 43, 1-26
  6. Takahashi, A. I.; Veiga, F. J. B.; Ferraz, H. G. Int. J. Pharm. Sci. Rev. Res. 2012, 12, 1-7
  7. Earle, R. R.; Tedlapu, V. K.; Ayalasomayajula, L. U. Res. J. Pharm. Technol. 2017, 10, 301-306
  8. Hirlekar, R.; Kadam, V. AAPS PharmSciTech 2009, 10, 276-281
  9. Kane, R.; Naik, S.; Bumrela, S.; Kuchekar, B. J. Pharm. Res. 2009, 2, 1359-1364
  10. Hirlekar, R. S.; Sonawane, S. N.; Kadam, V. J. AAPS PharmSciTech 2009, 10, 858-863
  11. Muankaew, C.; Jansook, P.; Stefansson, E.; Loftsson, T. Int. J. Pharm. 2014, 474, 80-90
  12. Tosco, P.; Rolando, B.; Fruttero, R.; Henchoz, Y.; Martel, S.; Carrupt, P.; Gasco, A. Helv. Chim. Acta 2008, 91, 468-482
  13. Cagigal, E.; Gonzalez, L.; Alonso, R. M.; Jimenez, R. M. J. Pharm. Biomed. Anal. 2001, 26, 477-486
  14. Brewster, M. E.; Loftsson, T. Adv. Drug Deliv. Rev. 2007, 59, 645-666
  15. Liu, L.; Guo, Q. X. J. Incl. Phenom. Macrocycl. Chem. 2002, 42, 1-14
  16. Bauer, M.; Harris, R. K.; Rao, R. C.; Apperley, D. C.; Rodger, C. A. J. Chem. Soc. Perkin Trans. 1998, 2, 475-481
  17. Byard, S. J.; Herbert, J. M. Tetrahedron 1999, 55, 5931-5936
  18. Bettinetti, G.; Novák, C.; Sorrenti, M. J. Therm. Anal. Calorim. 2002, 68, 517-529
  19. Franca, C. A.; Etcheverry, S. B.; Diez, R. P.; Williams, P. A. M. J. Raman Spectrosc. 2009, 40, 1296-1300
  20. Al Omari, M. M.; Zughul, M. B.; Davies, J. E. D.; Badwan, A. A. J. Pharm. Biomed. Anal. 2006, 41, 857-865
  21. Higuchi, T.; Connors, A. In Advances in Analytical Chemistry and Instrumentation Vol. 4; Reilley, C. N., Ed. Interscience Publishers: Hoboken, NJ, USA, 1964, pp. 117-211
  22. Zughul, M. B.; Badwan, A. A. J. Incl. Phenom. Mol. Recognit. Chem. 1998, 31, 243-264
  23. Zughul, M. B. J. Incl. Phenom. Macrocycl. Chem. 2007, 57, 525-530
  24. Cappello, B.; Maio, C.; Iervolino, M.; Miro, A. J. Incl. Phenom. Macrocycl. Chem. 2006, 54, 289-294.